Følg
Francesca De Franco
Francesca De Franco
TES Pharma
Verificeret mail på tespharma.com
Titel
Citeret af
Citeret af
År
Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells
A Viale, F De Franco, A Orleth, V Cambiaghi, V Giuliani, D Bossi, ...
Nature 457 (7225), 51-56, 2009
3832009
De novo NAD+ synthesis enhances mitochondrial function and improves health
E Katsyuba, A Mottis, M Zietak, F De Franco, V van der Velpen, K Gariani, ...
Nature 563 (7731), 354-359, 2018
3562018
Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist
G Rizzo, D Passeri, F De Franco, G Ciaccioli, L Donadio, G Rizzo, ...
Molecular pharmacology 78 (4), 617-630, 2010
2092010
Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat
A Roda, R Pellicciari, A Gioiello, F Neri, C Camborata, D Passeri, ...
Journal of Pharmacology and Experimental Therapeutics 350 (1), 56-68, 2014
662014
Discovery of 3α, 7α, 11β-trihydroxy-6α-ethyl-5β-cholan-24-oic acid (TC-100), a novel bile acid as potent and highly selective FXR agonist for enterohepatic disorders
R Pellicciari, D Passeri, F De Franco, S Mostarda, P Filipponi, C Colliva, ...
Journal of medicinal chemistry 59 (19), 9201-9214, 2016
562016
Pyrazole [3, 4-e][1, 4] thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists
M Marinozzi, A Carotti, E Sansone, A Macchiarulo, E Rosatelli, R Sardella, ...
Bioorganic & medicinal chemistry 20 (11), 3429-3445, 2012
552012
Probing the binding site of bile acids in TGR5
A Macchiarulo, A Gioiello, C Thomas, TWH Pols, R Nuti, C Ferrari, ...
ACS medicinal chemistry letters 4 (12), 1158-1162, 2013
542013
α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) inhibitors as novel modulators of de novo nicotinamide adenine dinucleotide (NAD+) biosynthesis
R Pellicciari, P Liscio, N Giacchè, F De Franco, A Carotti, J Robertson, ...
Journal of medicinal chemistry 61 (3), 745-759, 2018
412018
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells
M Roberti, F Schipani, G Bagnolini, D Milano, E Giacomini, F Falchi, ...
European Journal of Medicinal Chemistry 165, 80-92, 2019
382019
Garcinoic acid is a natural and selective agonist of pregnane X receptor
D Bartolini, F De Franco, P Torquato, R Marinelli, B Cerra, R Ronchetti, ...
Journal of Medicinal Chemistry 63 (7), 3701-3712, 2020
362020
Synthetic lethality in pancreatic cancer: Discovery of a new RAD51-BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with olaparib
G Bagnolini, D Milano, M Manerba, F Schipani, JA Ortega, D Gioia, ...
Journal of Medicinal Chemistry 63 (5), 2588-2619, 2020
332020
Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor
S Russo, M Incerti, M Tognolini, R Castelli, D Pala, I Hassan-Mohamed, ...
Molecules 18 (10), 13043-13060, 2013
182013
Synthesis of atypical bile acids for use as investigative tools for the genetic defect of 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency
A Gioiello, B Cerra, W Zhang, GP Vallerini, G Costantino, F De Franco, ...
The Journal of Steroid Biochemistry and Molecular Biology 144, 348-360, 2014
142014
A non-redundant function of cyclin E1 in hematopoietic stem cells
S Campaner, A Viale, S De Fazio, M Doni, F De Franco, L D'artista, ...
Cell Cycle 12 (23), 3663-3672, 2013
142013
Identification of RAD51–BRCA2 Inhibitors Using N-Acylhydrazone-Based Dynamic Combinatorial Chemistry
G Bagnolini, B Balboni, F Schipani, D Gioia, M Veronesi, F De Franco, ...
ACS Medicinal Chemistry Letters 13 (8), 1262-1269, 2022
72022
Innovations and Emerging Therapies to Combat Renal Cell Damage: NAD+ As a Drug Target
CL Manrique-Caballero, JA Kellum, H Gómez, F De Franco, N Giacche, ...
Antioxidants & Redox Signaling 35 (17), 1449-1466, 2021
72021
Structural basis of human dimeric α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase inhibition with TES-1025
M Cianci, N Giacchè, L Cialabrini, A Carotti, P Liscio, E Rosatelli, ...
Frontiers in Molecular Biosciences 9, 834700, 2022
32022
Development of 3α, 7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-sulfate sodium salt (INT-767): Process optimization, synthesis and characterization of metabolites
B Cerra, F Venturoni, M Souma, G Ceccarelli, AM Lozza, D Passeri, ...
European Journal of Medicinal Chemistry 242, 114652, 2022
22022
An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic …
SH Myers, L Poppi, F Rinaldi, M Veronesi, A Ciamarone, V Previtali, ...
European Journal of Medicinal Chemistry 265, 116114, 2024
12024
Chemical exploration of TGR5 functional hot-spots: Synthesis and structure-activity relationships of C7-and C23-Substituted cholic acid derivatives
E Rosatelli, A Carotti, B Cerra, F De Franco, D Passeri, R Pellicciari, ...
European Journal of Medicinal Chemistry 261, 115851, 2023
12023
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–20